~(177)Lu-DOTA-J591 MONOCLONAL ANTIBODY: CHEMISTRY, TOXICITY, DOSIMETRY AND CLINICAL EFFICACY: RIT OF PROSTATE CANCER USING ~(177)LU-J591 ANTI-PSMA ANTIBODYProstate specific membrane antigen (PSMA) is a transmembrane antigen virtually restricted to prostate tissue and the expression of which is ...
J591 mAb was labeled with 177 at a high specific activity (10-30 mCi/mg) using DOTA as the bifunctional chelate. The preclinical data in PSMA positive xenografts, strongly suggested that 177 mAb is an ideal radiopharmaceutical for RIT of metastatic PCa. Since October 2000, five clinical ...
Comparative biodistributions of In-111-DOTA-J591 and Lu-177-DOTA-J591: Ramifications for Y-90 dosimetry.SmithJones, P MSt Omer, SNavarro, VBander, N HGoldsmith, S JVallabhajosula, S
因此对于接受177Lu-DOTATAT E治疗患者的陪护人员,在整个治疗过程中即使长时间保持距离较近的接触也是安全的;对于医护人员,由于可能参与多次177Lu-DOTATATE治疗,且在其他核医学诊断和治疗实践中同样存在放射性暴露,因此建议遵从“合理做到尽可能低”原则,缩短与患者接触时间,与患者保持一定距离,正确穿戴铅衣,从时间、距离...
177Lu-J591; 117Lu-J591; 177Lu−J591; lutetium Lu 177 monoclonal antibody J591; TX591; TLX591; 177Lu-DOTA-Rosopatamab; 177Lu-DOTA-TLX591-CHO; 177Lu-DOTA-rosopatamb; 177Lu-TLX591; 177Lu-DOTA-TLX591 药品类别 创新药; 生物; 抗体; potential first-in-class; 放射性药物; 偶联药物...
PSMA 单克隆 抗体 (J591)由于相对分子质量较大 ,血液清除慢 ,对肿瘤组织渗透性差 ,骨髓抑制 的发生率较 高 ,限[14-15] 制了其在临床的推广应用. 海德堡大 学德国癌症中心于 2015 年最先开始实施177Lu-PSMA 的 RLT[16].177Lu-PSMA 的 RLT 具有血液清除 快,对肿瘤渗透性强的特点,能够在 肿瘤内 高度...
of [177Lu]Lu-DOTA-folate with and without pre-injected folic acid (FA). The data are decay-corrected and expressed as percentage of injected activity per gram tissue (% IA/g), reported as average ± SD obtained from each group of mice (n = 3–4) Eur J Nucl Med Mol Imaging (2021...
Here, we developed two 177Lu-labeled bivalent PSMA ligands with (DOTA-Alb-Bi-PSMA) or without an albumin-binding motif (DOTA-Bi-PSMA) to enhance radiotherapeutic efficacy with minimal toxicity. The results demonstrated that both 177Lu-labeled bivalent radioligands showed good stability, high ...
Benešová M, Schäfer M, Bauder-Wüst U, Afshar-Oromieh A, Kratochwil C, Mier W, et al. Preclinical evaluation of a tailor-made DOTA-conjugated PSMA inhibitor with optimized linker moiety for imaging and endoradiotherapy of prostate cancer. J Nucl Med. 2015;56(6):914–20. ...
Radioimmunotherapy of Metastatic Prostate Cancer with 177Lu-DOTAhuJ591 Anti Prostate Specific Membrane Antigen Specific Monoclonal Antibody[J] . Shankar Vallabha... Shankar,Vallabhajosula,Anastasia,... - 《Current Radiopharmaceuticals》 被引量: 35发表: 2016年 ...